New tool predicts deadly form of rare cancer

(Brigham and Women's Hospital) A tool to accurately determine which early-stage patients are at risk of dying from mycosis fungoides and which patients are likely to only require conventional therapy is desperately needed. Investigators from Brigham and Women's Hospital have found that next-generation, high-throughput sequencing of a specific gene (T-cell receptor beta or TCRB) is a stronger predictor of which early-stage patients will develop aggressive, progressive MF than any other established factor.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news